Insider Selling: ResMed Inc. (NYSE:RMD) CFO Sells $209,810.00 in Stock

ResMed Inc. (NYSE:RMDGet Free Report) CFO Brett Sandercock sold 1,000 shares of the stock in a transaction dated Monday, June 10th. The stock was sold at an average price of $209.81, for a total transaction of $209,810.00. Following the sale, the chief financial officer now directly owns 91,056 shares in the company, valued at $19,104,459.36. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

ResMed Stock Performance

RMD opened at $212.38 on Friday. ResMed Inc. has a twelve month low of $132.24 and a twelve month high of $229.97. The firm has a market capitalization of $31.20 billion, a PE ratio of 32.62, a PEG ratio of 2.07 and a beta of 0.68. The company has a current ratio of 3.04, a quick ratio of 1.97 and a debt-to-equity ratio of 0.22. The firm’s 50-day moving average price is $205.25 and its 200 day moving average price is $188.04.

ResMed (NYSE:RMDGet Free Report) last issued its earnings results on Thursday, April 25th. The medical equipment provider reported $2.13 earnings per share for the quarter, topping the consensus estimate of $1.91 by $0.22. The business had revenue of $1.20 billion for the quarter, compared to analysts’ expectations of $1.17 billion. ResMed had a return on equity of 24.43% and a net margin of 20.91%. The business’s revenue for the quarter was up 7.2% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.68 EPS. As a group, sell-side analysts expect that ResMed Inc. will post 7.7 EPS for the current fiscal year.

ResMed Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, June 13th. Shareholders of record on Thursday, May 9th were paid a $0.48 dividend. This represents a $1.92 dividend on an annualized basis and a dividend yield of 0.90%. The ex-dividend date of this dividend was Wednesday, May 8th. ResMed’s dividend payout ratio (DPR) is presently 29.49%.

Analyst Ratings Changes

A number of research firms recently weighed in on RMD. Royal Bank of Canada upped their price target on ResMed from $187.00 to $200.00 and gave the stock a “sector perform” rating in a report on Friday, April 26th. Mizuho reiterated a “buy” rating and set a $215.00 target price on shares of ResMed in a research report on Wednesday, March 27th. Oppenheimer cut their price target on shares of ResMed from $205.00 to $200.00 and set an “outperform” rating for the company in a report on Friday, April 26th. KeyCorp increased their price objective on shares of ResMed from $227.00 to $238.00 and gave the company an “overweight” rating in a report on Friday, April 26th. Finally, Needham & Company LLC boosted their target price on shares of ResMed from $224.00 to $236.00 and gave the stock a “buy” rating in a research note on Friday, April 26th. Four investment analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat, ResMed has a consensus rating of “Moderate Buy” and an average price target of $202.80.

Check Out Our Latest Report on ResMed

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Atlantic Edge Private Wealth Management LLC purchased a new position in ResMed during the fourth quarter worth about $27,000. Hall Laurie J Trustee acquired a new stake in shares of ResMed during the 1st quarter worth approximately $32,000. BOK Financial Private Wealth Inc. purchased a new stake in shares of ResMed during the 1st quarter valued at approximately $35,000. Planned Solutions Inc. acquired a new position in ResMed in the fourth quarter valued at approximately $34,000. Finally, Riverview Trust Co purchased a new position in ResMed in the first quarter worth approximately $42,000. Hedge funds and other institutional investors own 54.98% of the company’s stock.

About ResMed

(Get Free Report)

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. It operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes.

Further Reading

Insider Buying and Selling by Quarter for ResMed (NYSE:RMD)

Receive News & Ratings for ResMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed and related companies with's FREE daily email newsletter.